Psychiatry & Neurology Doctors in Titusville, FL Accepting Medicare

5 Psychiatry & Neurology doctors found. Showing 1 - 5

Dr. James Webb Cole Iii, MD Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 101 Dragonfly Dr, Titusville, FL 32780 Phone: 772-971-3829

Dr. Arvind Alex D'cruz, M.D.,M.R.C.P.(U.K) Psychiatry & Neurology - Diagnostic Neuroimaging Medicare: Accepting Medicare Assignments Practice Location: 951 N Washington Ave, Pmg. Hospitalist.neurology Dept, Titusville, FL 32796 Phone: 321-268-6111    Fax: 321-268-6360

Dr. Donald James Baracskay Ii, MD Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 2355 Truman Scarborough Way, Titusville, FL 32796 Phone: 321-603-6550

Remigio C. Villegas Jr., M.D. Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 6700 S Washington Ave, Titusville, FL 32780 Phone: 321-722-5200    Fax: 321-953-7510

Mira Sachdev, M.D. Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 860 Century Medical Dr, Titusville, FL 32796 Phone: 561-319-2120

News Archive

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

AiCuris announced today publication of preclinical data on AIC246, at the International Herpesvirus Workshop in Salt Lake City, Utah, USA from 24 – 29 July 2010. AIC246 is a novel anti-HCMV drug currently in clinical phase 2 testing.

Enhanced pharmacist care improves outcomes in patients with high blood pressure

Patients with high blood pressure are benefiting from the expanded role played by pharmacists in Alberta, according to a new study from the University of Alberta's Faculty of Medicine & Dentistry.

Ethnicity, race affect likelihood of finding suitable unrelated stem cell donors for cancer patients

Researchers at Moffitt Cancer Center and colleagues have published a study describing the greater difficulty in finding matched, unrelated donors for non-Caucasian patients who are candidates for hematopoietic cell transplantation (HCT).

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.

Read more Medical News

› Verified 4 days ago